Argument Preview / Featured

As we have been reporting, four cases being argued at the Federal Circuit in November attracted amicus briefs. One is Arbutus Biopharma Corp. v. Moderna, Inc., a patent case that has attracted several amicus briefs. In this case, Moderna appeals a district court’s ruling that its COVID-19 vaccine production under a government contract was not protected by 28 U.S.C. § 1498(a) for doses that were not administrated directly to U.S. government employees. On appeal, Moderna presents questions concerning statutory interpretation and the scope of the government-use defense in patent infringement litigation. This is our argument preview.

In its opening brief, Moderna argued the district court erred in allowing Arbutus and Genevant to pursue claims that Moderna indirectly infringed their patents by encouraging healthcare professionals to administer its COVID-19 vaccine. Moderna objected to the district court’s finding that “Moderna’s manufacturing . . . was ‘for the Government’ only if the Government . . . was the ‘intended recipient of the infringing product.'” Moderna contended 28 U.S.C. § 1498(a)—a federal law protecting companies manufacturing patented products for the government—should shield contractors from both direct and indirect infringement claims when they act with government authorization. Moderna argued the statute “relieve[s] the contractor entirely from liability of every kind” for qualifying government work, and patent owners should not be able to “cosmetically reframe their claims” to get around that protection. According to Moderna, allowing these claims to proceed would undermine the protections Congress intended to provide government contractors.

In its response brief, Arbutus asserted “clear language and decades of settled precedent dictate that what matters when applying § 1498 is whether the purchased goods are ‘for the Government’ in the most straightforward and obvious sense—is the United States government the direct beneficiary or not?” It contended that, because Moderna “cannot meet the long-established direct-benefit test,” it “attempts to supplant it with two alternative rules that no court ever has articulated, much less endorsed.”

In its reply brief, Moderna asserted “Plaintiff’s gerrymandered ‘direct-benefit test’ has no basis in § 1498.” Moderna argued the test “is a case-specific improvisation that contradicts text, precedent, and common sense.”

The case attracted four amicus briefs in support of reversal and seven amicus briefs in support of affirmance.

Oral argument in this case is scheduled to be heard on Thursday, November 5, at 10:00 am in Courtroom 402.